T1	Participants 0 173	Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type.
T2	Participants 274 328	long-term cholinergic treatment of Alzheimer's disease
T3	Participants 634 732	multicenter study comparing patches containing 30 mg and 60 mg physostigmine with a placebo patch.
T4	Participants 737 922	clinical trial followed the basic principles of the various guidelines on the evaluation of anti-dementia drugs, and included patients with mild to moderate probable Alzheimer's disease
T5	Participants 926 1009	total of 204 patients with probable Alzheimer's disease were included in the study.
T6	Participants 1010 1214	Of these, 136 patients were eligible for the according-to-protocol analysis of efficacy, 167 subjects for the intention-to-treat analysis of efficacy, and 181 patients were included in the safety analysis
